Argonaut Therapeutics
Is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut Therapeutics strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.
Our Mission
Argonaut’s Therapeutics' mission is to deliver hope to cancer patients through new drugs targeting arginine methylation.
Investors
The University of Oxford is a collegiate research university located in Oxford, England, United Kingdom. While having no known date of foundation, there is evidence of teaching as far back as 1096, making it the oldest university in the English-speaking world and the world’s second-oldest surviving university.
https://www.jw-pharma.co.kr/pharma/en/intro/pharma.jsp
Since the foundation in 1945, JW Pharmaceutical Corporation, based in Seoul, South Korea, has long been leading the hospital domestic market in pharmaceuticals, IV solutions, medical devices and diagnostics. JW is also reinforcing its global competitiveness through expanding CMO business with its world class high-tech manufacturing facilities. JW is focusing on innovative drug development through an internal R&D center along with JW CreaGene for cell therapy, JW Theriac in San Diego, USA and C&C Research Lab which is a joint venture company with Chugai Pharmaceutical Corporation.
Oxford Sciences Innovation find the most innovative ideas coming out of the University of Oxford, and invest in them to build world-class companies.
Partners
The Medical Sciences Division is an internationally recognised centre of excellence for biomedical and clinical research and teaching and is the largest of the four academic divisions within the University. The other three divisions are Humanities, Mathematical, Physical and Life Sciences and Social Sciences.
Over 5000 academics, researchers, NHS clinicians and GPs, and administrative staff, 1500 graduate and 1600 undergraduate students, together contribute to our extensive and exemplary research, teaching and clinical portfolios.
We aim to be the best university biomedical institution in Europe and amongst the best five biomedical institutions in the world, and have been ranked number one for the last ten years in the Times Higher Education World University Rankings for clinical, pre-clinical and health sciences - the only non-North American institution to be top-ranked by THE in any subject discipline.
Target discovery helps identifying drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The centre aims to link recent advances in genetics, genomics, cell and chemical biology for improved drug target discovery.
o2h group has a track record of nurturing and investing in emerging life science and tech companies, covering biotech, small molecule, biologics, digital health, software and social enterprise.